Mingshan Niu

Xuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

Journal: Frontiers in oncology

Published: December 10, 2025

STAT3 inhibition eradicates multiple myeloma stem-like cells and induces immunogenic cell death.

STAT3 inhibition eradicates multiple myeloma stem-like cells and induces immunogenic cell death.

Journal: Blood science (Baltimore, Md.)

Published: October 21, 2025

Bioinformatic analysis of venetoclax sensitivity and resistance mechanisms in acute myeloid leukemia

Bioinformatic analysis of venetoclax sensitivity and resistance mechanisms in acute myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 07, 2025

Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.

Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.

Journal: Cancer cell international

Published: September 13, 2024

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Journal: Blood

Published: August 19, 2024

Discovery of novel third generation P-glycoprotein inhibitors bearing an azo moiety with MDR-reversing effect.

Discovery of novel third generation P-glycoprotein inhibitors bearing an azo moiety with MDR-reversing effect.

Journal: European journal of medicinal chemistry

Published: July 09, 2024

Retraction Note: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.

Retraction Note: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.

Journal: Cell death & disease

Published: March 05, 2024

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.

Journal: Cancer immunology, immunotherapy : CII

Published: January 12, 2024

Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.

Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.

Journal: Blood advances

Published: December 12, 2023

FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.

FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.

Journal: Science advances

Published: August 18, 2023

Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.

Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 22, 2023

Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment.

Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment.

Journal: Journal of translational medicine

Published: March 24, 2023

Showing 1-12 of 67

Last Updated: 09/26/2026